[{"id":"oliver-sartor","kind":"person","name":"A. Oliver Sartor","aka":[],"tldr":"Led VISION, the trial that made lutetium-PSMA the first radioligand therapy for prostate cancer.","summary":"Oliver Sartor was co-principal investigator of VISION, which showed 177Lu-PSMA-617 improves survival in PSMA-positive metastatic castration-resistant prostate cancer and led to Pluvicto's approval, and was a lead investigator of PSMAfore, which moved the therapy before chemotherapy. He also co-led ALSYMPCA (radium-223). He directs the radiopharmaceutical trials programme at Mayo Clinic.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Oliver_Sartor","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sartor%20O%5BAuthor%5D%20PSMA%20lutetium"}],"tags":["prostate","radioligand","trialist"],"related":["lu-177","ra-223"],"indications":["prostate"],"sections":[],"technologies":["radioligand-therapy","psma-pet"],"targets":["psma"],"drugs":["pluvicto"],"companies":[],"institutions":["mayo-clinic"],"pathways":[],"terms":[],"trials":["vision","psmafore","alsympca"],"people":[],"bottlenecks":[],"keyPapers":["paper-vision-nejm-2021"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology and Urology, Mayo Clinic","institutionId":"mayo-clinic","specialisms":["Prostate cancer","Radioligand therapy","PSMA-targeted therapy","Radium-223"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sartor%20O%5BAuthor%5D%20PSMA%20lutetium"}],"papers":[{"title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer (VISION)","journal":"NEJM","year":2021,"doi":"10.1056/NEJMoa2107322"},{"title":"Alpha emitter radium-223 and survival in metastatic prostate cancer (ALSYMPCA)","journal":"NEJM","year":2013,"doi":"10.1056/NEJMoa1213755"}]},{"id":"amir-iravani","kind":"person","name":"Amir Iravani","aka":[],"tldr":"A nuclear medicine physician-scientist who worked on the practice-changing TheraP and LuPSMA trials in Australia and has moved through Fred Hutchinson to UCLA in 2026 to build a new hospital theranostics programme.","summary":"Amir Iravani trained at Melbourne's Peter MacCallum Cancer Centre, where he was a co-investigator on the LuPSMA phase 2 trial and the TheraP randomised phase 2 trial (177Lu-PSMA-617 versus cabazitaxel), including work on PSMA and FDG PET as predictive and prognostic biomarkers. He later became Theranostics Clinical Director at Fred Hutchinson Cancer Center and Associate Professor of Radiology at the University of Washington, where he studied how PSMA/FDG dual-tracer selection criteria (TheraP-style versus VISION-style) affect outcomes with 177Lu-PSMA-617.\n\nIn July 2026 he joined UCLA Health as Director of the Theranostics Program and Vice Chair of Clinical Research in the newly established Department of Nuclear Medicine and Theranostics, tasked with expanding clinical trials and research collaborations in precision radiopharmaceutical care.","asOf":"2026-09-22","links":[{"label":"UCLA Health news release, September 2026","url":"https://www.uclahealth.org/news/release/nuclear-medicine-physician-scientist-dr-amir-iravani-joins"},{"label":"Becker's Hospital Review coverage","url":"https://www.beckershospitalreview.com/radiology/ucla-health-taps-fred-hutch-theranostics-leader/"}],"tags":["PSMA","theranostics","clinician"],"related":["therap","pluvicto","ucla-jonsson","lu-177"],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Associate Professor and Vice Chair of Clinical Research, Director of the Theranostics Program, Department of Nuclear Medicine and Theranostics, David Geffen School of Medicine at UCLA (from July 2026; previously Theranostics Clinical Director, Fred Hutchinson Cancer Center, and Associate Professor of Radiology, University of Washington, 2022-2026)","specialisms":["PSMA radioligand therapy trials","dosimetry","dual-tracer (PSMA/FDG) patient selection"],"profiles":[{"label":"UW Radiology profile (2022-2026)","url":"https://rad.uw.edu/people/airavani"},{"label":"UCLA Health announcement, September 2026","url":"https://www.uclahealth.org/news/release/nuclear-medicine-physician-scientist-dr-amir-iravani-joins"}],"papers":[{"title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","journal":"The Lancet","year":2021,"doi":"10.1016/S0140-6736(21)00237-3"},{"title":"[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study","journal":"The Lancet Oncology","year":2018,"doi":"10.1016/S1470-2045(18)30198-0"},{"title":"PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received 177Lu-PSMA-617","journal":"Journal of Nuclear Medicine","year":2025,"doi":"10.2967/jnumed.124.268578"}]},{"id":"andrei-iagaru","kind":"person","name":"Andrei Iagaru","aka":[],"tldr":"A Stanford nuclear medicine professor who led the division for a decade and has published widely on new PET tracers, from FAPI scans of fibrosis-related proteins to whole-body PET scanners that image the entire body at once.","summary":"Andrei Iagaru joined Stanford in 2007 and served as Chief of the Division of Nuclear Medicine and Molecular Imaging from 2016 (co-chief from 2011); Stanford's faculty listing as of September 2026 names Erin Grady as interim division chief, indicating a leadership transition, while Iagaru continues as Professor of Radiology. He has authored or co-authored more than 200 peer-reviewed papers spanning 68Ga-PSMA-11 and 18F-DCFPyL PET for prostate cancer, gastrin-releasing peptide receptor (GRPR) imaging, and fibroblast activation protein inhibitor (FAPI) PET.\n\nHe has been a prominent voice in the debate over whether FAPI PET will replace FDG PET in oncologic staging, arguing for a complementary rather than replacement role, and is active in total-body and long-axial-field-of-view PET research and international PET/MRI consensus guideline efforts with EANM, SNMMI and ISMRM.","asOf":"2026-09-22","links":[{"label":"Stanford Profiles","url":"https://cap.stanford.edu/profiles/frdActionServlet?choiceId=printerprofile&profileversion=full&profileId=8156"},{"label":"Stanford Nuclear Medicine faculty page","url":"https://med.stanford.edu/nuclearmedicine/people/faculty.html"}],"tags":["PSMA","FAPI","total-body PET","clinician"],"related":["fapi-pet","ga68-psma-11","pet-mri","f-18","ga-68"],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Radiology (Nuclear Medicine), Stanford University Medical Center (formerly Chief of the Division of Nuclear Medicine and Molecular Imaging, 2016-2026; Stanford's faculty page as of September 2026 lists Erin Grady, MD, as Interim Division Chief)","specialisms":["FAPI PET","total-body and long-axial-field-of-view PET","PSMA PET"],"profiles":[{"label":"Stanford Profiles CV","url":"https://cap.stanford.edu/profiles/viewCV?facultyId=8156&name=Andrei_Iagaru"},{"label":"Stanford Nuclear Medicine faculty page","url":"https://med.stanford.edu/nuclearmedicine/people/faculty.html"},{"label":"Google Scholar","url":"https://scholar.google.com/citations?user=8RwEbvgAAAAJ&hl=en"}],"papers":[{"title":"Will FAPI PET/CT Replace FDG PET/CT in the Next Decade?-Counterpoint: No, not so fast!","journal":"American Journal of Roentgenology","year":2020,"url":"https://pubmed.ncbi.nlm.nih.gov/33356420/"},{"title":"Gallium 68 PSMA-11 PET/MR imaging in patients with intermediate- or high-risk prostate cancer","journal":"Radiology","year":2018,"url":"https://pubs.rsna.org/doi/10.1148/radiol.2018172232"},{"title":"International EANM-SNMMI-ISMRM consensus recommendation for PET/MRI in oncology","journal":"European Journal of Nuclear Medicine and Molecular Imaging","year":2023}]},{"id":"chris-parker","kind":"person","name":"Chris C. Parker","aka":[],"tldr":"London radiation oncologist who led ALSYMPCA, the trial that showed radium-223 lengthens survival in prostate cancer that has spread to bone, and RADICALS-RT, which showed radiotherapy after prostatectomy can safely wait until the PSA rises.","summary":"Chris Parker is a clinical oncologist at The Royal Marsden and The Institute of Cancer Research. He was first author of the 2013 New England Journal of Medicine report of ALSYMPCA, in which the alpha-emitter radium-223 improved overall survival in castration-resistant prostate cancer with bone metastases, and of the 2020 Lancet report of RADICALS-RT, which found that early salvage radiotherapy on PSA rise was as good as adjuvant radiotherapy after prostatectomy, with less toxicity.","asOf":"2026-09-18","links":[],"tags":["prostate","radiotherapy","trialist"],"related":["ra-223"],"indications":["prostate-mcrpc","prostate-bcr","prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["royal-marsden"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-alsympca-radium-223-nejm-2013"],"journals":[],"dependsOn":[],"notes":[],"role":"Clinical oncologist, The Royal Marsden and The Institute of Cancer Research","institutionId":"royal-marsden","specialisms":["Prostate radiotherapy","Radium-223","Post-prostatectomy radiotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Parker%5BAuthor%5D"}],"papers":[{"title":"ALSYMPCA: alpha emitter radium-223 and survival in metastatic prostate cancer with bone metastases","journal":"New England Journal of Medicine","year":2013,"url":"https://doi.org/10.1056/NEJMoa1213755","doi":"10.1056/NEJMoa1213755"},{"title":"RADICALS-RT: timing of radiotherapy after radical prostatectomy","journal":"The Lancet","year":2020,"url":"https://doi.org/10.1016/S0140-6736(20)31553-1","doi":"10.1016/S0140-6736(20)31553-1"}]},{"id":"clemens-kratochwil","kind":"person","name":"Clemens Kratochwil","aka":[],"tldr":"Clemens Kratochwil reported the first patients treated with actinium-225 PSMA therapy.","summary":"Clemens Kratochwil is a nuclear medicine physician at Heidelberg University Hospital, working within the NCT and DKFZ network. His specialisms are targeted alpha therapy, PSMA radioligands and dosimetry in prostate cancer. He reported the first patients treated with actinium-225 PSMA therapy, published in the Journal of Nuclear Medicine as 225Ac-PSMA-617 for PSMA-targeted alpha-radiation therapy of metastatic castration-resistant prostate cancer. That first clinical experience launched the alpha-emitter era in prostate cancer, and he continues to work on actinium-225 PSMA agents and their dosimetry. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kratochwil%20C%5BAuthor%5D%20225Ac%20PSMA"}],"tags":[],"related":["ac-225"],"indications":["prostate"],"sections":[],"technologies":["targeted-alpha-therapy"],"targets":["psma"],"drugs":["ac225-psma"],"companies":[],"institutions":["heidelberg-nct"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["journal-of-nuclear-medicine"],"dependsOn":[],"notes":[],"role":"Nuclear medicine physician, Heidelberg University Hospital","institutionId":"heidelberg-nct","specialisms":["Targeted alpha therapy","PSMA radioligands","Dosimetry"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kratochwil%20C%5BAuthor%5D%20225Ac%20PSMA"}],"papers":[{"title":"225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer","journal":"Journal of Nuclear Medicine","year":2016,"doi":"10.2967/jnumed.116.178673"}],"orcid":"0000-0003-1334-8260"},{"id":"dale-bailey","kind":"person","name":"Dale L. Bailey","aka":[],"tldr":"An Australian medical physicist who helped prove that SPECT scans, not just PET scans, can measure exact amounts of radioactivity in the body, which underpins accurate dosing of radioactive cancer treatments.","summary":"Dale Bailey has worked in nuclear medicine medical physics for more than 35 years and holds joint appointments as Principal Medical Physics Specialist at Sydney's Royal North Shore Hospital and Professor in the Faculty of Medicine and Health at the University of Sydney. With Kathy Willowson, he authored widely cited reviews establishing quantitative SPECT/CT as a technique for measuring absolute radioactivity concentration (kBq/mL) comparable in principle to quantitative PET, work that underlies modern post-therapy dosimetry for lutetium-177 and other therapeutic radionuclides.\n\nHe directs the Sydney Vital Northern Translational Cancer Research Centre and has developed methodology for calibrating and validating PET and SPECT scanners for quantitative multicentre clinical trials using non-standard radionuclides such as iodine-124 and iodine-131. His methods work is closely aligned with, and has fed into, the EANM/SNMMI physics and dosimetry standards used across the radiopharmaceutical field.","asOf":"2026-09-22","links":[{"label":"University of Sydney CV","url":"https://www.sydney.edu.au/AcademicProfiles/profile/resource?urlid=dale.bailey&type=cv"},{"label":"Quantitative SPECT/CT review, EJNMMI 2014","url":"https://pubmed.ncbi.nlm.nih.gov/24037503/"}],"tags":["physics","dosimetry","SPECT"],"related":["spect-ct","radioligand-dosimetry","in-vivo-dosimetry","i-124","lu-177","i-131"],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Principal Medical Physics Specialist, Department of Nuclear Medicine, Royal North Shore Hospital, Sydney; Professor, Faculty of Medicine and Health, University of Sydney","specialisms":["quantitative SPECT/CT","radionuclide dosimetry","PET/SPECT camera calibration"],"profiles":[{"label":"University of Sydney academic profile / CV","url":"https://www.sydney.edu.au/AcademicProfiles/profile/resource?urlid=dale.bailey&type=cv"},{"label":"Google Scholar","url":"https://scholar.google.com.au/citations?user=0Mq8GUMAAAAJ&hl=en"}],"papers":[{"title":"An evidence-based review of quantitative SPECT imaging and potential clinical applications","journal":"Journal of Nuclear Medicine","year":2013,"doi":"10.2967/jnumed.112.111476"},{"title":"Quantitative SPECT/CT: SPECT joins PET as a quantitative imaging modality","journal":"European Journal of Nuclear Medicine and Molecular Imaging","year":2014,"doi":"10.1007/s00259-013-2542-4"},{"title":"A Method for Validating PET and SPECT Cameras for Quantitative Clinical Imaging Trials Using Novel Radionuclides","journal":"Journal of Nuclear Medicine","year":2025,"doi":"10.2967/jnumed.124.268578"}]},{"id":"declan-murphy","kind":"person","name":"Declan G. Murphy","aka":[],"tldr":"Urologist who co-led proPSMA, the trial that showed PSMA PET should replace CT and bone scan for staging prostate cancer.","summary":"Declan Murphy was co-principal investigator of proPSMA, the randomised trial showing PSMA PET-CT is 27% more accurate than conventional imaging for staging high-risk prostate cancer, the evidence behind PSMA PET's adoption in guidelines. He directs GU oncology at Peter Mac, leads robotic surgery, and chairs the ANZUP theranostics and surgical sub-committees.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Murphy%20DG%5BAuthor%5D%20PSMA%20prostate"}],"tags":["prostate","imaging","surgery"],"related":[],"indications":["prostate"],"sections":[],"technologies":["psma-pet"],"targets":["psma"],"drugs":[],"companies":[],"institutions":["peter-mac","anzup"],"pathways":[],"terms":[],"trials":["propsma"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["european-urology"],"dependsOn":[],"notes":[],"role":"Director of Genitourinary Oncology, Peter MacCallum Cancer Centre","institutionId":"peter-mac","specialisms":["Urological surgery","PSMA PET","Robotic prostatectomy","Prostate cancer staging"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Murphy%20DG%5BAuthor%5D%20PSMA%20prostate"}],"papers":[{"title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA)","journal":"Lancet","year":2020,"doi":"10.1016/S0140-6736(20)30314-7"},{"title":"Prostate-specific membrane antigen positron emission tomography (PSMA-PET) for local staging of prostate cancer: a systematic review and meta-analysis","journal":"European Urology","year":2020}],"orcid":"0000-0002-7500-5899"},{"id":"delphine-chen","kind":"person","name":"Delphine L. Chen","aka":[],"tldr":"A Seattle-based nuclear medicine physician-scientist who ran the first human trial of a PET tracer that shows whether a tumour will respond to PARP-inhibitor drugs, and who now directs nuclear medicine and molecular imaging therapy at the Fred Hutchinson Cancer Center.","summary":"Delphine Chen holds the Wil B. Nelp, MD Endowed Professorship in Nuclear Medicine at the University of Washington and directs Molecular Imaging and Therapy at Fred Hutchinson Cancer Center, a role she has held since 2019; from January 2026 she also became Clinical Research Director for Radiology at Fred Hutch. She was principal investigator on the first-in-human trial of 18F-fluorthanatrace (18F-FTT), a PET tracer for imaging PARP-1 expression to help predict response to PARP-inhibitor drugs, developed with a patent held by Washington University.\n\nHer clinical practice covers the full range of oncologic PET and nuclear medicine therapies, and she has led trials using 68Ga-PSMA-11 PET to predict prostate cancer response to standard therapies. She currently serves SNMMI as President of the Center for Molecular Imaging, Innovation, and Translation.","asOf":"2026-09-22","links":[{"label":"Fred Hutch faculty profile","url":"https://www.fredhutch.org/en/faculty-lab-directory/chen-delphine.html"},{"label":"UW Radiology profile","url":"https://rad.uw.edu/people/dlchen7"}],"tags":["PARP PET","clinician-scientist"],"related":["parp-pet","parp","snmmi","f-18","ga-68"],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor, Clinical Research Division, Fred Hutchinson Cancer Center; Professor of Radiology, University of Washington; Clinical Research Director for Radiology, Fred Hutch (from January 2026; Director of Molecular Imaging and Therapy, Fred Hutch, since 2019)","specialisms":["PARP PET imaging","PET methods development","radioligand therapy multidisciplinary care"],"profiles":[{"label":"Fred Hutch faculty profile","url":"https://www.fredhutch.org/en/faculty-lab-directory/chen-delphine.html"},{"label":"UW Radiology profile","url":"https://rad.uw.edu/people/dlchen7"}],"papers":[{"title":"PET Imaging of PARP Expression Using 18F-Olaparib","journal":"Journal of Nuclear Medicine","year":2019,"doi":"10.2967/jnumed.118.219733"},{"title":"A PET Radiotracer for Imaging Poly (ADP-Ribose) Polymerase-1","journal":"Radiology","year":2022,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8830434/"},{"title":"Pilot study: PARP1 imaging in advanced prostate cancer","journal":"Molecular Imaging and Biology","year":2022,"url":"https://digitalcommons.wustl.edu/oa_4/3816"}]},{"id":"ebrahim-delpassand","kind":"person","name":"Ebrahim S. Delpassand","aka":[],"tldr":"The nuclear medicine physician who founded and leads Excel Diagnostics in Houston, a radiopharmaceutical therapy centre that also runs early trials of new radioligands.","summary":"Ebrahim Delpassand is Chief Executive Officer and medical director of Excel Diagnostics and Nuclear Oncology Center in Houston, which its site describes as a Radiopharmaceutical Therapy Center of Excellence designated by the Society of Nuclear Medicine and Molecular Imaging, offering PET-CT and other imaging, radionuclide therapy and clinical trials. He has been an investigator on early trials of somatostatin and PSMA radioligands. His publications are listed on PubMed.","asOf":"2026-09-17","links":[{"label":"Excel Diagnostics","url":"https://www.exceldiagnostics.com/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Delpassand+ES%5BAuthor%5D"}],"tags":["leadership"],"related":[],"indications":[],"sections":[],"technologies":["radioligand-therapy","psma-pet"],"targets":[],"drugs":[],"companies":[],"institutions":["excel-diagnostics-nuclear-oncology"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer and Medical Director, Excel Diagnostics and Nuclear Oncology Center","institutionId":"excel-diagnostics-nuclear-oncology","specialisms":["Nuclear medicine","Radiopharmaceutical therapy","Molecular imaging","Radiopharmaceutical trials"],"profiles":[{"label":"Excel Diagnostics","url":"https://www.exceldiagnostics.com/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Delpassand+ES%5BAuthor%5D"}],"papers":[]},{"id":"emily-bergsland","kind":"person","name":"Emily K. Bergsland","aka":[],"tldr":"Neuroendocrine tumour specialist who helps design the trials that set treatment for these rare cancers.","summary":"Emily Bergsland is Professor of Medicine and Associate Director for Education at the UCSF Helen Diller Family Comprehensive Cancer Center. A medical oncologist focused on gastroenteropancreatic neuroendocrine tumours, she chaired the Alliance A021202 trial of pazopanib versus placebo in progressive carcinoid tumours and co-authors national neuroendocrine tumour treatment guidelines. Her papers include NCCN guidance on the management of advanced gastroenteropancreatic neuroendocrine tumours, a review of systemic therapies for advanced gastrointestinal carcinoid tumours and the A021202 trial report. Her record links to lutetium-177 dotatate, somatostatin receptor 2 and VEGF-directed therapy, and she leads UCSF's cancer education programmes.","asOf":"2026-09-08","links":[{"label":"UCSF profile","url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Emily%20K.%20Bergsland"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bergsland%20EK%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Emily%20K.%20Bergsland"}],"tags":[],"related":["lu-177"],"indications":["neuroendocrine"],"sections":[],"technologies":["radioligand-therapy"],"targets":["sstr2"],"drugs":["lutathera"],"companies":[],"institutions":["ucsf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine; Associate Director for Education, UCSF Helen Diller Family Comprehensive Cancer Center","institutionId":"ucsf","specialisms":["Neuroendocrine tumours","Gastrointestinal oncology","Clinical trials"],"profiles":[{"label":"UCSF profile","url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Emily%20K.%20Bergsland"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bergsland%20EK%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Emily%20K.%20Bergsland"}],"papers":[{"title":"Management of Advanced Gastroenteropancreatic Neuroendocrine Tumors","journal":"Journal of the National Comprehensive Cancer Network","year":2025,"url":"https://doi.org/10.6004/jnccn.2025.5012","doi":"10.6004/jnccn.2025.5012"},{"title":"Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors","journal":"Hematology/Oncology Clinics of North America","year":2016,"url":"https://doi.org/10.1016/j.hoc.2015.09.002","doi":"10.1016/j.hoc.2015.09.002"},{"title":"Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (Alliance A021202)","journal":"Journal of Clinical Oncology (ASCO Annual Meeting abstract)","year":2019,"url":"https://doi.org/10.1200/JCO.2019.37.15_suppl.4005","doi":"10.1200/JCO.2019.37.15_suppl.4005"}]},{"id":"erik-mittra","kind":"person","name":"Erik S. Mittra","aka":[],"tldr":"A Stanford-trained nuclear medicine doctor who leads the theranostics programme at Oregon Health & Science University and treats neuroendocrine tumour patients with radioactive peptide therapy.","summary":"Erik Mittra trained through the MD/PhD programme at Stony Brook University and completed nuclear medicine residency and PET/CT fellowship at Stanford, where he was faculty for eight years before joining Oregon Health & Science University (OHSU) in 2018. He is now Chief of Nuclear Medicine and Molecular Imaging and Director of Radiopharmaceutical Therapeutics at OHSU, running its multidisciplinary neuroendocrine tumour treatment programme.\n\nHis research focuses on peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE, including as a co-author on the substudy dosimetry analysis of the pivotal NETTER-1 trial, and on 90Y radioembolisation dosimetry using fused MAA-SPECT imaging. He has published extensively on FDG and NaF PET applications in oncology dating back to his Stanford years.","asOf":"2026-09-22","links":[{"label":"OHSU provider profile","url":"https://www.ohsu.edu/providers/erik-s-mittra-md-phd"},{"label":"NETRF specialist profile","url":"https://netrf.org/specialist/erik-mittra-md-phd/"}],"tags":["neuroendocrine","PRRT","clinician"],"related":["lutathera","netter-1","radioembolisation-tare","prrt","lu-177","y-90"],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Diagnostic Radiology; Chief, Nuclear Medicine and Molecular Imaging; Director, Radiopharmaceutical Therapeutics, Oregon Health & Science University","specialisms":["neuroendocrine tumour theranostics","PRRT","radioembolisation dosimetry"],"profiles":[{"label":"OHSU provider profile","url":"https://www.ohsu.edu/providers/erik-s-mittra-md-phd"}],"papers":[{"title":"Dosimetry of [177Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial","journal":"Journal of Nuclear Medicine","year":2025,"doi":"10.2967/jnumed.124.268903"},{"title":"Prognostic Utility of 90Y Radioembolization Dosimetry Based on Fusion 99mTc-Macroaggregated Albumin-99mTc-Sulfur Colloid SPECT","journal":"Journal of Nuclear Medicine","year":2013,"url":"https://pubmed.ncbi.nlm.nih.gov/24136932/"}]},{"id":"frederik-giesel","kind":"person","name":"Frederik Giesel","aka":[],"tldr":"Frederik Giesel co-developed FAPI PET imaging and now leads nuclear medicine in Düsseldorf.","summary":"Frederik Giesel is Director of Nuclear Medicine at University Hospital Düsseldorf, having previously worked at Heidelberg University Hospital within the NCT and DKFZ network. His specialisms are molecular imaging, FAPI PET and PSMA theranostics. He co-led the first-in-human FAPI PET studies in Heidelberg, and his Journal of Nuclear Medicine paper reported the biodistribution and preliminary dosimetry of two DOTA-containing FAP-targeting agents imaged with 68Ga-FAPI PET/CT. He continues to develop FAP-targeted imaging and therapy in Düsseldorf. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Giesel%20FL%5BAuthor%5D%20FAPI"}],"tags":[],"related":["ga-68"],"indications":[],"sections":[],"technologies":["fapi-pet"],"targets":["fap"],"drugs":[],"companies":[],"institutions":["heidelberg-nct"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["journal-of-nuclear-medicine"],"dependsOn":[],"notes":[],"role":"Director of Nuclear Medicine, University Hospital Düsseldorf; formerly Heidelberg","institutionId":"heidelberg-nct","specialisms":["Molecular imaging","FAPI PET","PSMA theranostics"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Giesel%20FL%5BAuthor%5D%20FAPI"}],"papers":[{"title":"68Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents","journal":"Journal of Nuclear Medicine","year":2019,"doi":"10.2967/jnumed.118.215913"}]},{"id":"heiko-schoder","kind":"person","name":"Heiko Schöder","aka":["Heiko Schoder"],"tldr":"A nuclear medicine doctor who runs the molecular imaging service at Memorial Sloan Kettering and has spent years studying how PET scans taken partway through chemotherapy for lymphoma can predict which patients need more or less treatment.","summary":"Heiko Schöder has been Chief of the Molecular Imaging and Therapy Service in the Department of Radiology at Memorial Sloan Kettering Cancer Center since 2018, after joining MSK in 2001 and rising through clinical director and deputy chief roles. His research programme centres on interim and end-of-treatment FDG PET as a prognostic and response-adapted-therapy tool in Hodgkin and non-Hodgkin lymphoma, including analyses of the CALGB 50303 and SWOG S0816 trials and pooled analyses of interim-PET Deauville scoring in advanced Hodgkin lymphoma.\n\nHe is a regular co-author of the SNMMI Highlights Lectures summarising annual advances in oncologic PET and therapy, and has published on theranostics more broadly, including a widely cited review of radiotheranostics challenges and opportunities with Lisa Bodei, Ken Herrmann and colleagues. His clinical practice also spans cardiac and head-and-neck cancer nuclear imaging.","asOf":"2026-09-22","links":[{"label":"MSK doctor profile","url":"https://www.mskcc.org/cancer-care/doctors/heiko-schoder"},{"label":"CALGB 50303 interim-PET analysis, Blood 2020","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7316220/"}],"tags":["lymphoma","FDG PET","clinician"],"related":["mskcc","lisa-bodei","rathl","fdg-pet"],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center; Professor of Radiology, Weill Cornell Medical College","institutionId":"mskcc","specialisms":["FDG PET in lymphoma","response-adapted therapy","theranostics"],"profiles":[{"label":"MSK doctor profile","url":"https://www.mskcc.org/cancer-care/doctors/heiko-schoder"}],"papers":[{"title":"Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial","journal":"Blood","year":2020,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7316220/"},{"title":"Radiotheranostics in oncology: current challenges and emerging opportunities","journal":"Nature Reviews Clinical Oncology","year":2022,"doi":"10.1038/s41571-022-00652-y"},{"title":"2022 SNMMI Highlights Lecture: Oncology and Therapy, Part 1","journal":"Journal of Nuclear Medicine","year":2022,"url":"https://pubmed.ncbi.nlm.nih.gov/36456112/"}]},{"id":"jason-lewis","kind":"person","name":"Jason S. Lewis","aka":[],"tldr":"Radiochemist who built the zirconium-89 immuno-PET platform and MSKCC's radiopharmaceutical pipeline.","summary":"Jason Lewis developed methods for labelling antibodies with zirconium-89 that made immuno-PET a clinical reality, including 89Zr-trastuzumab and 89Zr-J591 PSMA imaging, and leads a laboratory translating new radiotracers and radioligand therapies from chemistry to first-in-human trials. He directs radiochemistry at MSKCC and has trained many of the field's leaders.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lewis%20JS%5BAuthor%5D%20zirconium-89%20PET"}],"tags":["radiochemistry","immuno-pet","theranostics"],"related":["zr-89"],"indications":[],"sections":[],"technologies":["immuno-pet","her2-pet","radioligand-therapy"],"targets":["her2","psma"],"drugs":[],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["journal-of-nuclear-medicine"],"dependsOn":[],"notes":[],"role":"Emily Tow Jackson Chair in Oncology and Chief Attending, Radiochemistry and Imaging Sciences Service, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["Radiochemistry","Immuno-PET","Radiopharmaceutical development","Targeted radiotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lewis%20JS%5BAuthor%5D%20zirconium-89%20PET"}],"papers":[{"title":"89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo","journal":"Journal of Nuclear Medicine","year":2010,"doi":"10.2967/jnumed.110.077982"},{"title":"Immuno-PET of HER2-positive breast cancer with 89Zr-trastuzumab: a first-in-human study","journal":"Journal of Nuclear Medicine","year":2016}]},{"id":"jeremie-calais","kind":"person","name":"Jeremie Calais","aka":[],"tldr":"Runs the UCLA theranostics trials that test PSMA imaging against conventional scans and lutetium against chemotherapy.","summary":"Jeremie Calais is Associate Professor and Director of the Clinical Research Program in the Ahmanson Translational Theranostics Division at UCLA, part of the UCLA Jonsson Comprehensive Cancer Center. A nuclear medicine physician specialising in PSMA PET and radioligand therapy, he leads prospective PSMA PET and PSMA radioligand therapy trials, including the head-to-head comparison of PSMA PET with fluciclovine PET and dosimetry research. His papers include the Lancet Oncology comparative imaging trial of 18F-fluciclovine and 68Ga-PSMA-11 PET-CT in early biochemical recurrence after prostatectomy and the Journal of Nuclear Medicine RESIST-PC phase 2 trial of 177Lu-PSMA-617 in the UCLA cohort. His work centres on prostate cancer theranostics.","asOf":"2026-09-08","links":[{"label":"UCLA profile","url":"https://www.uclahealth.org/providers?q=Jeremie%20Calais"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Calais%20J%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Jeremie%20Calais"}],"tags":[],"related":["f-18","ga-68","lu-177"],"indications":["prostate"],"sections":[],"technologies":["psma-pet","radioligand-therapy"],"targets":["psma"],"drugs":[],"companies":[],"institutions":["ucla-jonsson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["journal-of-nuclear-medicine"],"dependsOn":[],"notes":[],"role":"Associate Professor; Director, Clinical Research Program, Ahmanson Translational Theranostics Division, UCLA","institutionId":"ucla-jonsson","specialisms":["PSMA PET","Radioligand therapy","Clinical trials"],"profiles":[{"label":"UCLA profile","url":"https://www.uclahealth.org/providers?q=Jeremie%20Calais"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Calais%20J%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Jeremie%20Calais"}],"papers":[{"title":"18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial","journal":"Lancet Oncology","year":2019,"url":"https://doi.org/10.1016/s1470-2045(19)30415-2","doi":"10.1016/s1470-2045(19)30415-2"},{"title":"Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with (177)Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort","journal":"Journal of Nuclear Medicine","year":2021,"url":"https://doi.org/10.2967/jnumed.121.261982","doi":"10.2967/jnumed.121.261982"}]},{"id":"johannes-czernin","kind":"person","name":"Johannes Czernin","aka":[],"tldr":"Nuclear medicine leader who helped bring PSMA PET and radioligand therapy to the United States.","summary":"Johannes Czernin is Chief of the Ahmanson Translational Theranostics Division at UCLA, within the UCLA Jonsson Comprehensive Cancer Center, and editor-in-chief of the Journal of Nuclear Medicine. A nuclear medicine physician specialising in PSMA theranostics and PET imaging, he co-led the UCLA and UCSF prospective PSMA PET trials behind FDA approval and the US experience with 177Lu-PSMA-617, now known as lutetium-177 vipivotide tetraxetan. His papers include the JAMA Oncology prospective single-arm trial assessing 68Ga-PSMA-11 PET accuracy in localising recurrent prostate cancer and an Annual Review of Medicine article on molecular imaging in the development of cancer therapeutics. He helped bring PSMA PET and radioligand therapy to the United States.","asOf":"2026-09-08","links":[{"label":"UCLA profile","url":"https://www.uclahealth.org/providers?q=Johannes%20Czernin"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Czernin%20J%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Johannes%20Czernin"}],"tags":[],"related":["ga-68","lu-177"],"indications":["prostate"],"sections":[],"technologies":["psma-pet","radioligand-therapy","pet"],"targets":["psma"],"drugs":["pluvicto"],"companies":[],"institutions":["ucla-jonsson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Ahmanson Translational Theranostics Division, UCLA","institutionId":"ucla-jonsson","specialisms":["Nuclear medicine","PSMA theranostics","PET imaging"],"profiles":[{"label":"UCLA profile","url":"https://www.uclahealth.org/providers?q=Johannes%20Czernin"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Czernin%20J%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Johannes%20Czernin"}],"papers":[{"title":"Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial","journal":"JAMA Oncology","year":2019,"url":"https://doi.org/10.1001/jamaoncol.2019.0096","doi":"10.1001/jamaoncol.2019.0096"},{"title":"Molecular imaging in the development of cancer therapeutics","journal":"Annual Review of Medicine","year":2006,"url":"https://doi.org/10.1146/annurev.med.57.080904.190431","doi":"10.1146/annurev.med.57.080904.190431"}]},{"id":"jonathan-strosberg","kind":"person","name":"Jonathan R. Strosberg","aka":[],"tldr":"Led NETTER-1, the trial that made lutetium dotatate the first approved radioligand therapy for neuroendocrine tumours.","summary":"Jonathan Strosberg was principal investigator of NETTER-1, which showed 177Lu-DOTATATE reduces the risk of progression by 79% in midgut neuroendocrine tumours and led to Lutathera's approval, the first radioligand therapy approved for a solid tumour and the template for PSMA-targeted therapy. He co-leads the NETTER-2 and COMPETE programmes and chairs the North American Neuroendocrine Tumor Society guidelines.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Strosberg%20J%5BAuthor%5D%20neuroendocrine%20lutetium"}],"tags":["neuroendocrine","radioligand","trialist"],"related":["lu-177"],"indications":["neuroendocrine"],"sections":[],"technologies":["radioligand-therapy"],"targets":["sstr2"],"drugs":["lutathera"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["compete"],"people":[],"bottlenecks":[],"keyPapers":["paper-netter-2-lancet-2024"],"journals":[],"dependsOn":[],"notes":[],"role":"Section Head, Neuroendocrine Tumor Program, Moffitt Cancer Center","specialisms":["Neuroendocrine tumours","Peptide receptor radionuclide therapy","Somatostatin analogues","Radioligand trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Strosberg%20J%5BAuthor%5D%20neuroendocrine%20lutetium"}],"papers":[{"title":"Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors (NETTER-1)","journal":"NEJM","year":2017,"doi":"10.1056/NEJMoa1607427"},{"title":"177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results","journal":"Lancet Oncology","year":2021,"doi":"10.1016/S1470-2045(21)00572-6"},{"title":"NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours","journal":"The Lancet","year":2024,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NETTER-2+lutetium+dotatate+first-line+Singh+Lancet"}]},{"id":"karim-fizazi","kind":"person","name":"Karim Fizazi","aka":[],"tldr":"Led LATITUDE and PEACE-1, which put abiraterone into first-line metastatic prostate cancer.","summary":"Karim Fizazi is Head of Medical Oncology at Gustave Roussy and Professor at Paris-Saclay, with links to Centre Oscar Lambret. His specialisms are prostate cancer, genitourinary oncology, hormone therapy and radioligand therapy. He is one of the most influential prostate cancer trialists of the past two decades, leading LATITUDE, the New England Journal of Medicine trial of abiraterone plus prednisone in high-risk metastatic castration-sensitive prostate cancer, and PEACE-1, the Lancet trial adding abiraterone to androgen deprivation therapy and docetaxel in de novo metastatic disease. He has also led studies of radium-223 and PSMA radioligands, and is linked to the ALSYMPCA trial. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fizazi%20K%5BAuthor%5D%20prostate%20abiraterone"}],"tags":[],"related":["ra-223"],"indications":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["abiraterone","radium-223"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["alsympca"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head of Medical Oncology, Gustave Roussy; Professor, Paris-Saclay","specialisms":["Prostate cancer","Genitourinary oncology","Hormone therapy","Radioligand therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fizazi%20K%5BAuthor%5D%20prostate%20abiraterone"}],"papers":[{"title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer (LATITUDE)","journal":"NEJM","year":2017,"doi":"10.1056/NEJMoa1704174"},{"title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1)","journal":"Lancet","year":2022,"doi":"10.1016/S0140-6736(22)00367-1"},{"title":"VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer","journal":"New England Journal of Medicine","year":2021,"url":"https://doi.org/10.1056/NEJMoa2107322","doi":"10.1056/NEJMoa2107322"},{"title":"ARAMIS: darolutamide in non-metastatic castration-resistant prostate cancer","journal":"New England Journal of Medicine","year":2019,"url":"https://doi.org/10.1056/NEJMoa1815671","doi":"10.1056/NEJMoa1815671"}]},{"id":"katherine-matthay","kind":"person","name":"Katherine K. Matthay","aka":[],"tldr":"Paediatric oncologist whose trials established transplant and 13-cis-retinoic acid for high-risk neuroblastoma.","summary":"Katherine Matthay is Professor Emerita of Pediatrics at UCSF, within the UCSF Helen Diller Family Comprehensive Cancer Center, and a neuroblastoma investigator with the Children's Oncology Group (COG). A paediatric oncologist and long-time chair of COG neuroblastoma studies, she led the CCG-3891 trial establishing myeloablative therapy and 13-cis-retinoic acid in high-risk neuroblastoma and pioneered 131I-MIBG therapy for relapsed disease. Her papers report the Children's Cancer Group trial of intensive chemotherapy, radiotherapy, autologous bone marrow transplantation and 13-cis-retinoic acid, and the long-term results of that randomised trial. Her work links iobenguane I-131 and radioligand therapy to paediatric neuroblastoma.","asOf":"2026-09-08","links":[{"label":"UCSF profile","url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Katherine%20K.%20Matthay"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Matthay%20KK%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Katherine%20K.%20Matthay"}],"tags":[],"related":["i-131"],"indications":["neuroblastoma"],"sections":[],"technologies":["radioligand-therapy"],"targets":[],"drugs":["i131-mibg"],"companies":[],"institutions":["ucsf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor Emerita of Pediatrics, UCSF; Children's Oncology Group neuroblastoma investigator","institutionId":"ucsf","specialisms":["Paediatric oncology","Neuroblastoma","MIBG therapy"],"profiles":[{"label":"UCSF profile","url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Katherine%20K.%20Matthay"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Matthay%20KK%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Katherine%20K.%20Matthay"}],"papers":[{"title":"Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group","journal":"New England Journal of Medicine","year":1999,"url":"https://doi.org/10.1056/NEJM199910143411601","doi":"10.1056/NEJM199910143411601"},{"title":"Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study","journal":"Journal of Clinical Oncology","year":2009,"url":"https://doi.org/10.1200/JCO.2007.13.8925","doi":"10.1200/JCO.2007.13.8925"}]},{"id":"ken-herrmann","kind":"person","name":"Ken Herrmann","aka":[],"tldr":"Nuclear medicine leader who co-led VISION and runs one of the world's largest theranostics programmes.","summary":"Ken Herrmann was a lead investigator of VISION and of the German multicentre 177Lu-PSMA-617 registry, and leads the Essen theranostics centre that has treated thousands of patients with PSMA and somatostatin receptor radioligands. He has chaired the EANM oncology committee, co-authored the Lancet Oncology series on theranostics, and leads trials of alpha emitters and new targets such as FAP.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Herrmann%20K%5BAuthor%5D%20theranostics%20PSMA"}],"tags":["radioligand","nuclear-medicine","germany"],"related":["lu-177"],"indications":["prostate","neuroendocrine"],"sections":[],"technologies":["radioligand-therapy","psma-pet","fapi-pet"],"targets":["psma","fap"],"drugs":["pluvicto","lutathera"],"companies":[],"institutions":["essen-wtz","eanm"],"pathways":[],"terms":[],"trials":["vision"],"people":[],"bottlenecks":[],"keyPapers":["paper-vision-nejm-2021"],"journals":[],"dependsOn":[],"notes":[],"role":"Chair of Nuclear Medicine, University Hospital Essen","institutionId":"essen-wtz","specialisms":["Theranostics","PSMA radioligand therapy","Nuclear medicine","Radiopharmaceutical trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Herrmann%20K%5BAuthor%5D%20theranostics%20PSMA"}],"papers":[{"title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer (VISION)","journal":"NEJM","year":2021,"doi":"10.1056/NEJMoa2107322"},{"title":"Radiotheranostics: a roadmap for future development","journal":"Lancet Oncology","year":2020,"doi":"10.1016/S1470-2045(19)30821-6"}],"orcid":"0000-0002-9662-7259"},{"id":"lisa-bodei","kind":"person","name":"Lisa Bodei","aka":[],"tldr":"An Italian-trained nuclear medicine doctor who helped develop the lutetium-177 dotatate treatment for neuroendocrine tumours and now leads targeted radionuclide therapy at Memorial Sloan Kettering in New York.","summary":"Lisa Bodei trained in nuclear medicine in Italy and worked at the European Institute of Oncology in Milan, where she ran early phase I-II studies of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) and published long-term toxicity data across hundreds of neuroendocrine tumour patients. She moved to Memorial Sloan Kettering Cancer Center, where she is Director of Targeted Radionuclide Therapy in the Molecular Imaging and Therapy Service, and is a substudy author on the dosimetry component of the pivotal NETTER-1 trial that supported Lutathera's approval.\n\nShe co-authored the joint IAEA/EANM/SNMMI practical guidance on PRRT and is an associate editor of the Journal of Nuclear Medicine. Her current work extends theranostics beyond somatostatin receptors to new targets such as DLL3 in neuroendocrine and small-cell lung cancer.","asOf":"2026-09-22","links":[{"label":"MSK doctor profile","url":"https://www.mskcc.org/cancer-care/doctors/lisa-bodei"},{"label":"NETTER-1 dosimetry substudy, JNM 2025","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11876735/"}],"tags":["neuroendocrine","PRRT","clinician"],"related":["lutathera","netter-1","prrt","mskcc","lu-177"],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Attending Physician and Director of Targeted Radionuclide Therapy, Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center; Professor of Radiology, Weill Cornell Medical College","specialisms":["peptide receptor radionuclide therapy (PRRT)","dosimetry","neuroendocrine tumour theranostics"],"profiles":[{"label":"MSK doctor profile","url":"https://www.mskcc.org/cancer-care/doctors/lisa-bodei"},{"label":"NETRF board of advisors biography","url":"https://netrf.org/about-netrf/board-of-advisors/"}],"papers":[{"title":"The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours","journal":"European Journal of Nuclear Medicine and Molecular Imaging","year":2013,"doi":"10.1007/s00259-012-2330-6"},{"title":"Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study","journal":"European Journal of Nuclear Medicine and Molecular Imaging","year":2011,"doi":"10.1007/s00259-011-1902-1"},{"title":"Dosimetry of [177Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial","journal":"Journal of Nuclear Medicine","year":2025,"doi":"10.2967/jnumed.124.268903"},{"title":"Radiotheranostics in oncology: current challenges and emerging opportunities","journal":"Nature Reviews Clinical Oncology","year":2022,"doi":"10.1038/s41571-022-00652-y"}]},{"id":"louise-emmett","kind":"person","name":"Louise Emmett","aka":[],"tldr":"Nuclear medicine physician who leads ENZA-p and the PSMA imaging trials shaping Australian theranostics.","summary":"Louise Emmett (St Vincent's Hospital, Sydney) was principal investigator of ENZA-p, the ANZUP trial showing that adding 177Lu-PSMA-617 to enzalutamide delays progression in castration-resistant prostate cancer, and led the PRIMARY study of PSMA PET for diagnosis. She co-leads the ANZUP theranostics programme and writes widely used guidance on PSMA PET reporting.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Emmett%20L%5BAuthor%5D%20PSMA"}],"tags":["prostate","radioligand","australia"],"related":["lu-177"],"indications":["prostate"],"sections":[],"technologies":["psma-pet","radioligand-therapy"],"targets":["psma"],"drugs":["pluvicto"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["european-urology"],"dependsOn":[],"notes":[],"role":"Director of Theranostics and Nuclear Medicine, St Vincent's Hospital Sydney; Professor, UNSW","specialisms":["PSMA theranostics","Nuclear medicine","Prostate cancer imaging","Radioligand trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Emmett%20L%5BAuthor%5D%20PSMA"}],"papers":[{"title":"[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial","journal":"Lancet Oncology","year":2024},{"title":"The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY)","journal":"European Urology","year":2021,"doi":"10.1016/j.eururo.2021.08.002"}],"orcid":"0000-0002-4895-7384"},{"id":"matthias-eiber","kind":"person","name":"Matthias Eiber","aka":[],"tldr":"A German nuclear medicine physician whose 2015 study of gallium-68 PSMA PET scanning for prostate cancer became one of the most-cited papers in the field, and who now leads theranostics research in Munich.","summary":"Matthias Eiber led the seminal 2015 Journal of Nuclear Medicine study evaluating hybrid 68Ga-PSMA-11 PET/CT in 248 patients with biochemical recurrence after radical prostatectomy, a paper that is credited with driving global adoption of PSMA PET imaging. Working within Markus Schwaiger's department at TUM's Klinikum rechts der Isar, he subsequently helped develop and validate PSMA-I&T and compared 68Ga-PSMA-11 against 18F-PSMA-1007.\n\nHe leads the Theranostics Section at his department (since 2020) and is a co-author of the PROMISE miTNM framework for standardised PSMA-PET reporting and of RECIP 1.0, a framework for assessing radiographic response to PSMA-targeted radioligand therapy. He continues to publish extensively on PSMA PET-guided radioligand therapy dosimetry and outcome prediction, including work linked to the PSMAddition trial.","asOf":"2026-09-22","links":[{"label":"TUM CV page","url":"https://nuklearmedizin.mri.tum.de/de/lebenslauf-prof-dr-med-matthias-eiber"},{"label":"68Ga-PSMA-11 PET/CT biochemical recurrence study, JNM 2015","url":"https://jnm.snmjournals.org/content/56/5/668"}],"tags":["PSMA","PET","clinician"],"related":["ga68-psma-11","psma-pet","tum-munich","psmaddition","f-18","ga-68"],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor and Head of the Theranostics Section, Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich","institutionId":"tum-munich","specialisms":["PSMA PET","PSMA radioligand therapy","prostate cancer imaging biomarkers"],"profiles":[{"label":"TUM Klinik für Nuklearmedizin CV (German)","url":"https://nuklearmedizin.mri.tum.de/de/lebenslauf-prof-dr-med-matthias-eiber"},{"label":"TUM research portal (FIS)","url":"https://portal.fis.tum.de/en/persons/matthias-eiber/"}],"papers":[{"title":"Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy","journal":"Journal of Nuclear Medicine","year":2015,"doi":"10.2967/jnumed.115.154153"},{"title":"Matched-Pair Comparison of 68Ga-PSMA-11 PET/CT and 18F-PSMA-1007 PET/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical Prostatectomy","journal":"Journal of Nuclear Medicine","year":2020,"doi":"10.2967/jnumed.119.229187"},{"title":"Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT","journal":"Journal of Nuclear Medicine","year":2018,"doi":"10.2967/jnumed.117.198119"},{"title":"[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial","journal":"The Lancet","year":2026,"url":"https://portal.fis.tum.de/en/organisations/department-of-nuclear-medicine/"}]},{"id":"hofman-michael","kind":"person","name":"Michael Hofman","aka":[],"tldr":"Led proPSMA and TheraP, the trials that proved PSMA PET beats conventional imaging and that lutetium-PSMA beats chemotherapy.","summary":"Michael Hofman is Professor of Nuclear Medicine and Director of the Prostate Cancer Theranostics and Imaging Centre of Excellence at the Peter MacCallum Cancer Centre in Melbourne. He led proPSMA, which proved that PSMA PET-CT beats conventional imaging for staging high-risk prostate cancer before curative-intent surgery or radiotherapy, and TheraP, the ANZUP trial that showed lutetium-177 PSMA-617 beats cabazitaxel chemotherapy in metastatic castration-resistant prostate cancer. His publications include the proPSMA and TheraP reports, and his trials made Australia a global centre of theranostics. He now leads trials of earlier-line and combination radioligand therapy.","asOf":"2026-09-08","links":[{"label":"Peter MacCallum Cancer Centre","url":"https://www.petermac.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hofman%20MS%5BAuthor%5D%20PSMA"}],"tags":[],"related":["lu-177"],"indications":["prostate"],"sections":[],"technologies":["psma-pet","radioligand-therapy"],"targets":["psma"],"drugs":["pluvicto"],"companies":[],"institutions":["peter-mac"],"pathways":[],"terms":[],"trials":["propsma","therap"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Nuclear Medicine; Director, Prostate Cancer Theranostics and Imaging Centre of Excellence","institutionId":"peter-mac","specialisms":["Theranostics","PSMA PET","Lutetium-PSMA therapy","Nuclear medicine"],"profiles":[{"label":"Peter MacCallum Cancer Centre","url":"https://www.petermac.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hofman%20MS%5BAuthor%5D%20PSMA"}],"papers":[{"title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA)","journal":"Lancet","year":2020,"doi":"10.1016/S0140-6736(20)30314-7"},{"title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP)","journal":"Lancet","year":2021,"doi":"10.1016/S0140-6736(21)00237-3"}],"orcid":"0000-0001-8622-159X"},{"id":"michael-morris","kind":"person","name":"Michael J. Morris","aka":[],"tldr":"Principal investigator of the VISION trial that made lutetium-PSMA a standard prostate cancer treatment.","summary":"Michael J. Morris is Prostate Cancer Section Head on the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center. He is a medical oncologist known as principal investigator of the VISION trial, which made lutetium-177 PSMA radioligand therapy a standard prostate cancer treatment, and co-led PSMAfore and PSMA PET studies. His selected papers report lutetium-177 PSMA-617 for metastatic castration-resistant prostate cancer and the PSMAfore comparison against a change of androgen receptor pathway inhibitor in taxane-naive patients. He chaired the Alliance genitourinary committee and focuses on radioligand therapy and imaging biomarkers.","asOf":"2026-09-08","links":[{"label":"MSK profile","url":"https://www.mskcc.org/cancer-care/doctors/michael-morris"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Morris%20MJ%5BAuthor%5D"}],"tags":[],"related":["lu-177"],"indications":["prostate"],"sections":[],"technologies":["radioligand-therapy","psma-pet"],"targets":["psma"],"drugs":["pluvicto"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":["vision","psmafore"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Prostate Cancer Section Head, Genitourinary Oncology Service","institutionId":"mskcc","specialisms":["Prostate cancer","Radiopharmaceuticals","PSMA theranostics"],"profiles":[{"label":"MSK profile","url":"https://www.mskcc.org/cancer-care/doctors/michael-morris"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Morris%20MJ%5BAuthor%5D"}],"papers":[{"title":"Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer","journal":"New England Journal of Medicine","year":2021,"url":"https://doi.org/10.1056/NEJMoa2107322","doi":"10.1056/NEJMoa2107322"},{"title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore)","journal":"Lancet","year":2024,"url":"https://doi.org/10.1016/S0140-6736(24)01653-2","doi":"10.1016/S0140-6736(24)01653-2"}]},{"id":"michael-lassmann","kind":"person","name":"Michael Lassmann","aka":[],"tldr":"A German medical physicist who has led the physics section of Würzburg's nuclear medicine department for three decades and helped set the international standards used to calculate radiation doses from radioactive cancer treatments.","summary":"Michael Lassmann has worked as a medical physics expert in the Department of Nuclear Medicine at University Hospital Würzburg since 1988, was appointed head of the department's physics section in 1994, and holds a full professorship on the university's medical faculty. Between 2001 and 2008 he chaired the EANM Dosimetry Committee and continues to serve as a senior advisor to it; in 2017 he received the SNMMI Loevinger-Berman Award, nuclear medicine's leading dosimetry prize.\n\nHis research spans internal dosimetry for peptide receptor radionuclide therapy and radioiodine therapy, bone-marrow dosimetry methods, and biodosimetry for radiation protection. He is a co-author of the EANM/SNMMI joint procedure guideline for 177Lu-labelled PSMA-targeted radioligand therapy and of the PSMA-I&T theranostic first-in-human studies, and has continued this line of work through his successor Johannes Tran-Gia's Heisenberg professorship in multimodal imaging and theranostics at Würzburg.","asOf":"2026-09-22","links":[{"label":"University Hospital Würzburg profile","url":"https://www.ukw.de/nuklearmedizin/team/nuklearmedizin-detail/name/lassmann-michael/"},{"label":"Lassmann receives 2017 Loevinger-Berman Award","url":"https://jnm.snmjournals.org/content/jnumed/58/8/14N.full.pdf"}],"tags":["physics","dosimetry"],"related":["radioligand-dosimetry","prrt","lu177-radioligand-therapy","richard-baum","lu-177"],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head of Medical Physics, Department of Nuclear Medicine, University Hospital Würzburg","specialisms":["internal dosimetry","radiation protection","PRRT and radioiodine dosimetry"],"profiles":[{"label":"University Hospital Würzburg staff page (German)","url":"https://www.ukw.de/nuklearmedizin/team/nuklearmedizin-detail/name/lassmann-michael/"},{"label":"ORCID","url":"https://orcid.org/0000-0002-2556-1977"},{"label":"DFG GEPRIS researcher profile","url":"https://gepris.dfg.de/gepris/person/15130779"}],"papers":[{"title":"Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)","journal":"European Journal of Nuclear Medicine and Molecular Imaging","year":2023,"doi":"10.1007/s00259-023-06255-8"},{"title":"68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies","journal":"Journal of Nuclear Medicine","year":2015,"doi":"10.2967/jnumed.115.158550"}],"orcid":"0000-0002-2556-1977"},{"id":"neeta-pandit-taskar","kind":"person","name":"Neeta Pandit-Taskar","aka":[],"tldr":"A nuclear medicine doctor who spent 25 years at Memorial Sloan Kettering developing radioactive antibody treatments, including therapies for children with neuroblastoma, before moving to lead nuclear medicine at UPMC Hillman Cancer Center in 2025.","summary":"Neeta Pandit-Taskar joined Memorial Sloan Kettering Cancer Center (MSK) in 2000 and became Clinical Director of the Center for Radioimmunotargeted Imaging and Theranostics of the Ludwig Center for Cancer Immunotherapy, working on radiolabelled monoclonal antibodies and small molecules across lymphoma, prostate, renal and pancreatic cancers, and on 131I-omburtamab for paediatric leptomeningeal disease. In July 2025 she moved to become Chief of Nuclear Medicine and Vice-Chair of Clinical and Translational Research at UPMC Hillman Cancer Center and the University of Pittsburgh, also directing oncology imaging and theranostics there.\n\nShe served as president of the SNMMI Therapy Advisory Committee (Center for Molecular Imaging, Innovation, and Translation) from 2021 to 2023 and has advised the FDA and NRC on clinical use of actinium-225 alpha-emitting therapies. Her research spans imaging and therapy dosimetry for both antibody- and peptide-based radiopharmaceuticals, with particular depth in paediatric neuroblastoma imaging (18F-mFBG PET).","asOf":"2026-09-22","links":[{"label":"UPMC provider profile","url":"https://providers.upmc.com/provider/neeta-pandit-taskar/4210094"},{"label":"FDA-NRC Workshop presenter biography (actinium-225)","url":"https://www.fda.gov/media/152280/download"},{"label":"SNMMI Therapy Advisory Committee past presidents","url":"https://snmmi.org/AM/Web/About/About-SNMMI/Advisory-Committees/Therapy-Advisory-Committee/Past-Presidents.aspx"}],"tags":["theranostics","radioimmunotherapy","clinician"],"related":["mskcc","snmmi","neuroblastoma","f-18","ac-225","i-131"],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief of Nuclear Medicine and Vice-Chair of Clinical and Translational Research, UPMC Hillman Cancer Center / University of Pittsburgh (from July 2025; previously at Memorial Sloan Kettering Cancer Center, 2000-2025)","specialisms":["radioimmunotherapy","actinium-225 alpha therapy","paediatric nuclear medicine dosimetry"],"profiles":[{"label":"UPMC provider profile","url":"https://providers.upmc.com/provider/neeta-pandit-taskar/4210094"},{"label":"ORCID","url":"https://orcid.org/0000-0003-1551-2036"},{"label":"Former MSK profile (2000-2025)","url":"https://www.mskcc.org/cancer-care/doctors/neeta-pandit-taskar"}],"papers":[{"title":"Radioimmunoscintigraphy and pre-treatment dosimetry of 131I-omburtamab for planning treatment of leptomeningeal disease","journal":"Journal of Nuclear Medicine","year":2023,"doi":"10.2967/jnumed.122.265131"},{"title":"Safety Observations in Neuroblastoma Patients Undergoing 18F-mFBG PET","journal":"Nuclear Medicine Communications","year":2024,"doi":"10.1097/MNM.0000000000001938"}],"orcid":"0000-0003-1551-2036"},{"id":"paola-anna-erba","kind":"person","name":"Paola Anna Erba","aka":[],"tldr":"Italian nuclear medicine physician serving as President of the European Association of Nuclear Medicine.","summary":"Paola Anna Erba is President of the European Association of Nuclear Medicine (EANM) for the 2025-2026 term. She is a nuclear medicine physician and academic in Italy whose research covers molecular imaging, radioligand therapy and infection and inflammation imaging. As EANM President she leads the society's congress, guidelines and advocacy for nuclear medicine in oncology.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://eanm.org/the-eanm-community/organisation/board/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Erba+PA%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","nuclear medicine","theranostics"],"related":[],"indications":["neuroendocrine","prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["eanm"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President (2025-2026)","institutionId":"eanm","specialisms":["Nuclear medicine","Theranostics","Molecular imaging"],"profiles":[{"label":"Society page","url":"https://eanm.org/the-eanm-community/organisation/board/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Erba+PA%5BAuthor%5D"}],"papers":[{"title":"[18F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results","journal":"Radiation Oncology","year":2016,"doi":"10.1186/s13014-016-0586-x"},{"title":"Artificial intelligence and hybrid imaging: the best match for personalized medicine in oncology","journal":"European Journal of Hybrid Imaging","year":2020,"doi":"10.1186/s41824-020-00094-8"},{"title":"Differentiated Thyroid Cancer: A New Perspective with Radiolabeled Somatostatin Analogues for Imaging and Treatment of Patients","journal":"Thyroid®","year":2014,"doi":"10.1089/thy.2013.0225"}]},{"id":"peter-bartenstein","kind":"person","name":"Peter Bartenstein","aka":[],"tldr":"Peter Bartenstein is a nuclear medicine head whose department is a leading European PSMA theranostics centre.","summary":"Peter Bartenstein is Director of the Department of Nuclear Medicine at LMU Klinikum München. His specialisms are nuclear medicine, PSMA theranostics and neuro-imaging. His department is a leading European centre for PSMA PET and lutetium-177 PSMA radioligand therapy, and it co-developed 177Lu-PSMA-I&T. His papers include a dosimetry study of 177Lu-DKFZ-PSMA-617 as a new radiopharmaceutical for metastatic prostate cancer, the first clinical results of 18F-SiFAlin-TATE PET for imaging neuroendocrine tumours, and a European Urology study showing that 68Ga-PSMA PET/CT accurately stages lymph node regions before dissection in prostate cancer. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bartenstein%20P%5BAuthor%5D%20PSMA"}],"tags":[],"related":["f-18","ga-68","lu-177"],"indications":["prostate"],"sections":[],"technologies":["psma-pet","radioligand-therapy"],"targets":["psma"],"drugs":["lu177-psma-it"],"companies":[],"institutions":["lmu-munich"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Department of Nuclear Medicine, LMU Munich","institutionId":"lmu-munich","specialisms":["Nuclear medicine","PSMA theranostics","Neuro-imaging"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bartenstein%20P%5BAuthor%5D%20PSMA"}],"papers":[{"title":"Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer","journal":"European Journal of Nuclear Medicine and Molecular Imaging","year":2015,"doi":"10.1007/s00259-015-3174-7"},{"title":"Biodistribution and first clinical results of 18F-SiFAlin-TATE PET: a novel 18F-labeled somatostatin analog for imaging of neuroendocrine tumors","journal":"European Journal of Nuclear Medicine and Molecular Imaging","year":2019,"doi":"10.1007/s00259-019-04501-6"},{"title":"68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer","journal":"European Urology","year":2016,"doi":"10.1016/j.eururo.2015.12.051"}]},{"id":"phillip-kuo","kind":"person","name":"Phillip H. Kuo","aka":[],"tldr":"A nuclear medicine physician who helped write the eligibility scans used to select prostate cancer patients for the VISION trial of lutetium-177 PSMA-617, and who also sets national standards for brain PET scans used in Alzheimer's disease.","summary":"Phillip Kuo spent a decade as Chief of Nuclear Medicine at the University of Arizona before moving in 2024 to City of Hope Cancer Center in Duarte, California, where he is Division Chief of Nuclear Medicine and Director of Theranostics. He co-authored the explanation of the PSMA PET/CT selection criteria used in the pivotal VISION trial of 177Lu-PSMA-617, and has contributed to SNMMI appropriate-use-criteria panels for both PSMA PET and 177Lu-PSMA-617 radioligand therapy.\n\nHe also works in neurodegeneration imaging, serving on the Alzheimer's Association/SNMMI workgroup that issues updated appropriate use criteria for amyloid and tau PET, and as a co-author of the SNMMI/EANM procedure standard for brain FDG PET. This dual focus on prostate cancer theranostics and dementia imaging makes him one of relatively few nuclear medicine leaders bridging oncologic and neurologic molecular imaging standards.","asOf":"2026-09-22","links":[{"label":"City of Hope profile","url":"https://www.cityofhope.org/phillip-kuo"},{"label":"Why we did what we did, JNM 2022","url":"https://jnm.snmjournals.org/content/63/6/816"}],"tags":["PSMA","theranostics","brain PET","clinician"],"related":["vision","pluvicto","psma-pet","lu-177"],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor and Division Chief of Nuclear Medicine and Director of Theranostics, Department of Diagnostic Radiology, City of Hope Cancer Center (since 2024; previously Chief of Nuclear Medicine, University of Arizona, 2014-2024)","specialisms":["PSMA PET patient selection","amyloid and tau brain PET","appropriate use criteria"],"profiles":[{"label":"City of Hope profile","url":"https://www.cityofhope.org/phillip-kuo"}],"papers":[{"title":"Why We Did What We Did: PSMA-PET/CT Selection Criteria for the VISION Trial","journal":"Journal of Nuclear Medicine","year":2022,"doi":"10.2967/jnumed.121.263638"},{"title":"Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup","journal":"Journal of Nuclear Medicine","year":2025,"doi":"10.2967/jnumed.124.268756"},{"title":"SNMMI Procedure Standard/EANM Practice Guideline for Brain [18F]FDG PET Imaging, Version 2.0","journal":"Journal of Nuclear Medicine","year":2025}]},{"id":"pierre-vera","kind":"person","name":"Pierre Vera","aka":[],"tldr":"Nuclear medicine physician who directs Centre Henri Becquerel, the comprehensive cancer centre for the Rouen area in Normandy.","summary":"Professeur Pierre Vera is Directeur Général of Centre Henri Becquerel, the Centre de Lutte Contre le Cancer in Rouen. He is a nuclear medicine physician, and the centre's organisation page records his appointment to a five-year term beginning in 2017. He works with Artus Paty, Directeur Général Adjoint, who has been at the centre since 2016, supported by a Comité de Direction (CODIR) and a Conférence Médicale d'Etablissement (CME). The centre is overseen by a board of directors chaired by a representative of the State.","asOf":"2026-09-10","links":[{"label":"Source: Centre Henri Becquerel organisation page","url":"https://www.becquerel.fr/le-centre/decouvrir-le-centre/organisation/"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["lancet-oncology"],"dependsOn":[],"notes":[],"role":"Directeur Général (Director General), Centre Henri Becquerel","specialisms":["Nuclear medicine","Cancer imaging","Cancer centre management"],"profiles":[{"label":"Centre Henri Becquerel organisation page","url":"https://www.becquerel.fr/le-centre/decouvrir-le-centre/organisation/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vera+P%5BAuthor%5D+AND+Rouen"}],"papers":[{"title":"Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7–IFCT-1402): a multicentre, randomised, controlled phase 2 trial","journal":"The Lancet Oncology","year":2024,"doi":"10.1016/s1470-2045(24)00320-6"},{"title":"Radiomics: Principles and radiotherapy applications","journal":"Critical Reviews in Oncology/Hematology","year":2019,"doi":"10.1016/j.critrevonc.2019.03.015"},{"title":"Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort","journal":"Blood Cancer Journal","year":2018,"doi":"10.1038/s41408-018-0111-6"}]},{"id":"rafael-mariano-grossi","kind":"person","name":"Rafael Mariano Grossi","aka":[],"tldr":"Argentine diplomat leading the IAEA since 2019, whose Rays of Hope initiative expands radiotherapy and nuclear medicine access in low- and middle-income countries.","summary":"Rafael Mariano Grossi has been Director General of the International Atomic Energy Agency since December 2019. Under his leadership the IAEA launched Rays of Hope, an initiative to close the gap in access to radiotherapy, diagnostic imaging and nuclear medicine for cancer in countries with little or no capacity. His role is recorded in the public record.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.iaea.org/services/rays-of-hope"}],"tags":["leadership","radiotherapy","global health"],"related":[],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["iaea"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director General","institutionId":"iaea","specialisms":["International diplomacy","Nuclear applications in health","Global cancer care access"],"profiles":[{"label":"Institution profile","url":"https://www.iaea.org/services/rays-of-hope"}],"papers":[{"title":"The IAEA’s Rays of Hope leverages nuclear science and collaboration to fight cancer in developing countries","journal":"Journal of Cancer Policy","year":2022,"doi":"10.1016/j.jcpo.2022.100357"}]},{"id":"rahul-aggarwal","kind":"person","name":"Rahul Aggarwal","aka":[],"tldr":"Prostate oncologist studying how tumours transform to escape hormone therapy and how to target them with radioligands.","summary":"Rahul Aggarwal is Associate Director for Clinical Sciences at the UCSF Helen Diller Family Comprehensive Cancer Center. A medical oncologist specialising in prostate cancer, neuroendocrine prostate cancer and PSMA theranostics, he leads UCSF's early-phase and prostate cancer clinical research and defined treatment-emergent small-cell neuroendocrine prostate cancer, the way tumours transform to escape hormone therapy. His papers include a multi-institutional prospective study characterising that disease clinically and genomically, and a report on heterogeneous flare in PSMA PET tracer uptake after starting androgen pathway blockade. He leads PSMA radioligand and combination trials, including with lutetium-177 vipivotide tetraxetan.","asOf":"2026-09-08","links":[{"label":"UCSF profile","url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Rahul%20Aggarwal"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Aggarwal%20R%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Rahul%20Aggarwal"}],"tags":[],"related":["lu-177"],"indications":["prostate"],"sections":[],"technologies":["psma-pet","radioligand-therapy"],"targets":["psma"],"drugs":["pluvicto"],"companies":[],"institutions":["ucsf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Associate Director for Clinical Sciences, UCSF Helen Diller Family Comprehensive Cancer Center","institutionId":"ucsf","specialisms":["Prostate cancer","Neuroendocrine prostate cancer","PSMA theranostics"],"profiles":[{"label":"UCSF profile","url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Rahul%20Aggarwal"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Aggarwal%20R%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Rahul%20Aggarwal"}],"papers":[{"title":"Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study","journal":"Journal of Clinical Oncology","year":2018,"url":"https://doi.org/10.1200/JCO.2017.77.6880","doi":"10.1200/JCO.2017.77.6880"},{"title":"Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer","journal":"European Urology Oncology","year":2018,"url":"https://doi.org/10.1016/j.euo.2018.03.010","doi":"10.1016/j.euo.2018.03.010"}]},{"id":"richard-baum","kind":"person","name":"Richard P. Baum","aka":[],"tldr":"One of the pioneers of peptide receptor radionuclide therapy for neuroendocrine tumours, now practising at the Curanosticum theranostics centre in Wiesbaden.","summary":"Richard Baum is a specialist in nuclear medicine whom Curanosticum describes as one of the leading experts in therapeutic nuclear medicine and part of its medical team since 2020. The centre offers PET-CT, radioiodine therapy, PSMA radioligand therapy and DOTATOC receptor radionuclide therapy. Before Wiesbaden he built the theranostics programme at the Zentralklinik Bad Berka, where lutetium-177 and yttrium-90 labelled somatostatin analogues were used to treat thousands of patients with neuroendocrine tumours, work that preceded the approvals of lutetium-177 dotatate and lutetium-177 PSMA-617. His publications are listed on PubMed.","asOf":"2026-09-17","links":[{"label":"Curanosticum","url":"https://www.curanosticum.de/en/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Baum+RP%5BAuthor%5D+radionuclide"}],"tags":["leadership"],"related":["lu-177","y-90"],"indications":["neuroendocrine","prostate"],"sections":[],"technologies":["radioligand-therapy","lu177-radioligand-therapy","psma-pet"],"targets":[],"drugs":[],"companies":[],"institutions":["curanosticum"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Nuclear medicine specialist, Curanosticum Wiesbaden-Frankfurt","institutionId":"curanosticum","specialisms":["Nuclear medicine","Peptide receptor radionuclide therapy","PSMA radioligand therapy","Theranostics"],"profiles":[{"label":"Curanosticum","url":"https://www.curanosticum.de/en/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Baum+RP%5BAuthor%5D+radionuclide"}],"papers":[{"title":"Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors","journal":"New England Journal of Medicine","year":2017,"url":"https://doi.org/10.1056/NEJMoa1607427","doi":"10.1056/NEJMoa1607427","note":"Europe PMC author record matched by affiliation"},{"title":"FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0","journal":"European Journal of Nuclear Medicine and Molecular Imaging","year":2010,"url":"https://doi.org/10.1007/s00259-009-1297-4","doi":"10.1007/s00259-009-1297-4","note":"Europe PMC author record matched by affiliation"},{"title":"German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients","journal":"Journal of Nuclear Medicine","year":2017,"url":"https://doi.org/10.2967/jnumed.116.183194","doi":"10.2967/jnumed.116.183194","note":"Europe PMC author record matched by affiliation"}]},{"id":"robert-mach","kind":"person","name":"Robert H. Mach","aka":[],"tldr":"Robert Mach invented the PARP PET tracer FluorThanatrace that images DNA repair capacity in tumours.","summary":"Robert H. Mach is the Britton Chance Professor of Radiology and Director of PET Radiochemistry at the Abramson Cancer Center, University of Pennsylvania. He is a radiochemist known for inventing the PARP PET tracer fluorine-18 FluorThanatrace, which images DNA repair capacity in tumours, alongside other tracers for imaging drug targets. His selected paper reports FluorThanatrace uptake as a marker of PARP1 expression and activity in breast cancer. His laboratory's tracers enable PARP-inhibitor patient selection studies and molecular imaging with PET.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mach%20RH%5BAuthor%5D"}],"tags":[],"related":["f-18"],"indications":[],"sections":[],"technologies":["parp-pet","pet"],"targets":["parp"],"drugs":[],"companies":[],"institutions":["penn-abramson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Britton Chance Professor of Radiology; Director, PET Radiochemistry","institutionId":"penn-abramson","specialisms":["Radiochemistry","PARP PET","Molecular imaging"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mach%20RH%5BAuthor%5D"}],"papers":[{"title":"[18F]FluorThanatrace uptake as a marker of PARP1 expression and activity in breast cancer","journal":"American Journal of Nuclear Medicine and Molecular Imaging","year":2018}],"orcid":"0000-0002-7645-2869"},{"id":"rodney-hicks","kind":"person","name":"Rodney J. Hicks","aka":[],"tldr":"An Australian nuclear medicine pioneer who built Peter MacCallum Cancer Centre's molecular imaging and therapy service into a world-renowned unit over three decades, and now runs an independent theranostics centre in Melbourne.","summary":"Rodney Hicks directed cancer imaging and later the Centre for Molecular Imaging and Therapeutic Nuclear Medicine at Melbourne's Peter MacCallum Cancer Centre for around three decades, building a nuclear medicine service that helped pioneer clinical PET/CT in Australia and later 177Lu-PSMA-617 radioligand therapy. He was a senior author on the single-centre LuPSMA phase 2 trial and contributed to the proPSMA randomised trial of PSMA PET-CT for staging high-risk prostate cancer, and to methods for single-time-point SPECT/CT dosimetry of 177Lu-PSMA-617 therapy.\n\nAfter leaving Peter Mac in 2021, he founded the Melbourne Theranostic Innovation Centre (MTIC), where he is Executive Chairman and Chief Medical Officer, delivering theranostics clinical and research services in partnership with industry, while retaining a professorial appointment at the University of Melbourne.","asOf":"2026-09-22","links":[{"label":"Melbourne Theranostic Innovation Centre","url":"https://www.mtic.net.au/mtic-team/professor-rodney-hicks"},{"label":"proPSMA trial, The Lancet 2020","url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30314-7/fulltext"}],"tags":["PSMA","theranostics","clinician"],"related":["propsma","paper-propsma-hofman-lancet-2020","pluvicto","peter-mac","amir-iravani","lu-177"],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Founder, Executive Chairman and Chief Medical Officer, Melbourne Theranostic Innovation Centre; Professor of Medicine, University of Melbourne (previously Director, Centre for Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, until 2021)","specialisms":["theranostics programme building","neuroendocrine tumour PET","PSMA radioligand therapy dosimetry"],"profiles":[{"label":"Melbourne Theranostic Innovation Centre team page","url":"https://www.mtic.net.au/mtic-team/professor-rodney-hicks"},{"label":"Discovery Medicine biography","url":"https://www.discoverymedicine.com/Rodney-J-Hicks/about/"}],"papers":[{"title":"[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study","journal":"The Lancet Oncology","year":2018,"doi":"10.1016/S1470-2045(18)30198-0"},{"title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","journal":"The Lancet","year":2020,"doi":"10.1016/S0140-6736(20)30314-7"},{"title":"Radiation Dosimetry in 177Lu-PSMA-617 Therapy Using a Single Posttreatment SPECT/CT Scan: A Novel Methodology to Generate Time- and Tissue-Specific Dose Factors","journal":"Journal of Nuclear Medicine","year":2020,"doi":"10.2967/jnumed.119.233411"}]},{"id":"scott-tagawa","kind":"person","name":"Scott T. Tagawa","aka":["Scott Tagawa"],"tldr":"A cancer doctor at Weill Cornell in New York who has spent two decades testing PSMA-targeted radioactive treatments for prostate cancer, from the first antibody versions through to lutetium-177 PSMA-617.","summary":"Scott Tagawa is a genitourinary medical oncologist who has run early-phase trials of PSMA-targeted radioimmunotherapy since the 2000s, starting with the antibody 177Lu-J591 and continuing through the VISION trial of 177Lu-PSMA-617 (lutetium-177 vipivotide tetraxetan), where he was a co-investigator and author on subsequent safety and PSA-kinetics analyses. He is also a lead investigator on Trop-2-directed antibody-drug conjugate trials (TROPHY-U-01, TROPiCS-04) in urothelial cancer, giving him a cross-cutting view of radioligand and ADC approaches to genitourinary disease.\n\nAt Weill Cornell he directs the Genitourinary Oncology Program and the GU Oncology Research Program, and is the institution's principal investigator for the Alliance for Clinical Trials in Oncology. His group's early J591 dosimetry and fractionation studies helped establish the dose-response relationship for PSMA-targeted radioligand therapy that later informed 177Lu-PSMA-617 dosing.","asOf":"2026-09-22","links":[{"label":"Weill Cornell Medicine: Scott T. Tagawa","url":"https://weillcornell.org/sttagawa"},{"label":"VISION safety analysis, European Urology 2024","url":"https://www.sciencedirect.com/science/article/pii/S0302283824000206"}],"tags":["prostate","PSMA","clinician"],"related":["pluvicto","vision","lu-177"],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine and Urology, and Director of the Genitourinary Oncology Program, Weill Cornell Medicine / NewYork-Presbyterian","specialisms":["genitourinary medical oncology","PSMA radioligand and radioimmunotherapy","antibody-drug conjugates"],"profiles":[{"label":"Weill Cornell Medicine profile","url":"https://weillcornell.org/sttagawa"},{"label":"Weill Cornell VIVO research profile","url":"https://vivo.weill.cornell.edu/display/cwid-stt2007"}],"papers":[{"title":"Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer","journal":"Clinical Cancer Research","year":2013,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3778101/"},{"title":"TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors","journal":"Journal of Clinical Oncology","year":2021,"doi":"10.1200/JCO.20.03489"},{"title":"Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer","journal":"European Urology","year":2024,"url":"https://www.sciencedirect.com/science/article/pii/S0302283824000206"}]},{"id":"sandhu-shahneen","kind":"person","name":"Shahneen Sandhu","aka":[],"tldr":"Runs the medical oncology side of Peter Mac's theranostics programme, combining lutetium-PSMA with hormonal and immune therapies.","summary":"Shahneen Sandhu is a medical oncologist and Lead for Genitourinary Oncology Theranostics at the Peter MacCallum Cancer Centre in Melbourne. She runs the medical oncology side of Peter Mac's theranostics programme, leading combination trials such as PRINCE and UpFrontPSMA that pair lutetium-177 PSMA-617 with androgen receptor pathway inhibitors, chemotherapy and immunotherapy. Her publications include the UpFrontPSMA trial of sequential lutetium-177 PSMA-617 and docetaxel against docetaxel alone in metastatic hormone-sensitive prostate cancer. She also contributes to melanoma and early-phase research.","asOf":"2026-09-08","links":[{"label":"Peter MacCallum Cancer Centre","url":"https://www.petermac.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sandhu%20S%5BAuthor%5D%20Peter%20MacCallum%20prostate%20PSMA"}],"tags":[],"related":["lu-177"],"indications":["prostate"],"sections":[],"technologies":["radioligand-therapy"],"targets":["psma"],"drugs":["pluvicto"],"companies":[],"institutions":["peter-mac"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist; Lead, Genitourinary Oncology Theranostics, Peter Mac","institutionId":"peter-mac","specialisms":["Prostate cancer","Theranostics","Melanoma","Early-phase trials"],"profiles":[{"label":"Peter MacCallum Cancer Centre","url":"https://www.petermac.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sandhu%20S%5BAuthor%5D%20Peter%20MacCallum%20prostate%20PSMA"}],"papers":[{"title":"Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in metastatic hormone-sensitive prostate cancer (UpFrontPSMA)","journal":"Lancet Oncology","year":2024,"doi":"10.1016/S1470-2045(24)00440-6"}],"orcid":"0000-0002-8660-4475"},{"id":"song-shaoli","kind":"person","name":"Shaoli Song","aka":[],"tldr":"Leads the nuclear medicine group behind the first human TROP2 PET imaging, aiming to pick patients for TROP2 ADCs with a scan.","summary":"Shaoli Song is Professor and Director of the Department of Nuclear Medicine at Fudan University Shanghai Cancer Center. Her department developed and imaged the first TROP2-targeted PET tracers in patients with breast and other cancers, with the aim of selecting patients for TROP2 antibody-drug conjugates using a scan, alongside FAPI, HER2 and PSMA theranostic work. Her publications include head-to-head comparisons of FDG and FAPI PET-CT in recurrent soft tissue sarcoma and in platinum-sensitive recurrent ovarian cancer, and a study of preoperative FDG PET parameters for predicting microvascular invasion and recurrence in hepatocellular carcinoma. Her interests are PET tracer development and theranostics.","asOf":"2026-09-08","links":[{"label":"Fudan University Shanghai Cancer Center","url":"https://www.shca.org.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Song%20S%5BAuthor%5D%20Fudan%20TROP2%20PET"}],"tags":[],"related":[],"indications":[],"sections":[],"technologies":["trop2-pet","fapi-pet","her2-pet"],"targets":["trop2","fap"],"drugs":[],"companies":[],"institutions":["fuscc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor and Director, Department of Nuclear Medicine, Fudan University Shanghai Cancer Center","institutionId":"fuscc","specialisms":["Nuclear medicine","PET tracer development","TROP2 and HER2 PET","Theranostics"],"profiles":[{"label":"Fudan University Shanghai Cancer Center","url":"https://www.shca.org.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Song%20S%5BAuthor%5D%20Fudan%20TROP2%20PET"}],"papers":[{"title":"Head-to-head evaluation of [18F]FDG and [68 Ga]Ga-DOTA-FAPI-04 PET/CT in recurrent soft tissue sarcoma","journal":"European Journal of Nuclear Medicine and Molecular Imaging","year":2022,"doi":"10.1007/s00259-022-05700-4"},{"title":"Head-to-head comparison of [18F]-FDG and [68 Ga]-DOTA-FAPI-04 PET/CT for radiological evaluation of platinum-sensitive recurrent ovarian cancer","journal":"European Journal of Nuclear Medicine and Molecular Imaging","year":2023,"doi":"10.1007/s00259-022-06096-x"},{"title":"The value of preoperative 18F-FDG PET metabolic and volumetric parameters in predicting microvascular invasion and postoperative recurrence of hepatocellular carcinoma","journal":"Nuclear Medicine Communications","year":2021,"doi":"10.1097/mnm.0000000000001478"}]},{"id":"silke-gillessen","kind":"person","name":"Silke Gillessen","aka":[],"tldr":"Founder and chair of the APCCC consensus conference that guides advanced prostate cancer management worldwide.","summary":"Silke Gillessen (IOSI, Bellinzona) founded the Advanced Prostate Cancer Consensus Conference, whose biennial reports are the most widely used expert guidance on managing advanced prostate cancer where trial evidence is lacking. She was a lead investigator in STAMPEDE and in trials of PSMA radioligand therapy and helped establish the Swiss Group for Clinical Cancer Research GU programme.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gillessen%20S%5BAuthor%5D%20prostate%20consensus"}],"tags":["prostate","guidelines","switzerland"],"related":[],"indications":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["stampede"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["european-urology"],"dependsOn":[],"notes":[],"role":"Medical and Scientific Director, Oncology Institute of Southern Switzerland (IOSI), Bellinzona","specialisms":["Prostate cancer","Consensus guidelines","Genitourinary oncology","Treatment sequencing"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gillessen%20S%5BAuthor%5D%20prostate%20consensus"}],"papers":[{"title":"Management of patients with advanced prostate cancer: report from the Advanced Prostate Cancer Consensus Conference 2021","journal":"European Urology","year":2022,"doi":"10.1016/j.eururo.2022.04.002"},{"title":"Abiraterone for prostate cancer not previously treated with hormone therapy (STAMPEDE)","journal":"NEJM","year":2017,"doi":"10.1056/NEJMoa1702900"}],"orcid":"0000-0001-5746-6555"},{"id":"simron-singh","kind":"person","name":"Simron Singh","aka":[],"tldr":"Led NETTER-2, which moved lutetium dotatate into first-line treatment of higher-grade neuroendocrine tumours.","summary":"Simron Singh was principal investigator of NETTER-2, which showed first-line 177Lu-DOTATATE plus octreotide dramatically improves progression-free survival over high-dose octreotide in grade 2-3 gastroenteropancreatic neuroendocrine tumours, extending radioligand therapy to newly diagnosed patients. He has led Canadian and international NET guidelines and studies of NET epidemiology and patient-reported outcomes.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Singh%20S%5BAuthor%5D%20neuroendocrine%20NETTER-2"}],"tags":["neuroendocrine","radioligand","canada"],"related":["lu-177"],"indications":["neuroendocrine"],"sections":[],"technologies":["radioligand-therapy"],"targets":["sstr2"],"drugs":["lutathera"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-netter-2-lancet-2024"],"journals":[],"dependsOn":[],"notes":[],"role":"Medical Oncologist and Co-Director, Susan Leslie Clinic for Neuroendocrine Tumours, Sunnybrook Odette Cancer Centre","specialisms":["Neuroendocrine tumours","Radioligand therapy","Health services research","Guidelines"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Singh%20S%5BAuthor%5D%20neuroendocrine%20NETTER-2"}],"papers":[{"title":"[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2)","journal":"Lancet","year":2024,"doi":"10.1016/S0140-6736(24)00701-3"},{"title":"Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society guidelines for the diagnosis and management of patients with lung neuroendocrine tumors","journal":"Journal of Thoracic Oncology","year":2020,"doi":"10.1016/j.jtho.2020.06.021"},{"title":"NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours","journal":"The Lancet","year":2024,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NETTER-2+lutetium+dotatate+first-line+Singh+Lancet"}]},{"id":"stefano-fanti","kind":"person","name":"Stefano Fanti","aka":[],"tldr":"An Italian nuclear medicine professor who built one of Europe's busiest PET centres in Bologna and co-writes the international guidelines that tell doctors when and how to use PSMA PET scans in prostate cancer.","summary":"Stefano Fanti has directed the Nuclear Medicine Division and PET Unit at the Policlinico Sant'Orsola in Bologna since the early 2000s, building it into one of the most active European centres for non-FDG PET tracers, and is now also Vice Rector for Research at the University of Bologna. He co-authored the first standardised interpretive framework for PSMA-ligand PET (2017) and is a repeat co-author of the EAU-EANM-ESTRO-ESUR-SIOG prostate cancer guidelines that define the clinical role of PSMA PET in staging and restaging.\n\nHe has proposed and co-authored consensus criteria for assessing PSMA PET response to systemic therapy (the PSMA PET progression criteria, and consensus statements on PSMA PET/CT response assessment), and is a co-author of the EANM/SNMMI PSMA PET/CT procedure guideline versions 1.0 and 2.0. His work bridges the clinical and regulatory sides of PSMA imaging standardisation across Europe and the US.","asOf":"2026-09-22","links":[{"label":"University of Bologna profile","url":"https://www.unibo.it/sitoweb/s.fanti/en"},{"label":"Consensus statements on PSMA PET/CT response, EJNMMI 2021","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7835167/"}],"tags":["PSMA","guidelines","clinician"],"related":["psma-pet","ga68-psma-11","sant-orsola-bologna"],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Full Professor of Diagnostic Imaging and Director of Nuclear Medicine, University of Bologna / Policlinico Sant'Orsola; Vice Rector for Research, University of Bologna","institutionId":"sant-orsola-bologna","specialisms":["PSMA PET","PET response criteria","guideline development"],"profiles":[{"label":"University of Bologna staff page","url":"https://www.unibo.it/sitoweb/s.fanti/en"},{"label":"University of Bologna CV (English)","url":"https://www.unibo.it/sitoweb/s.fanti/cv-en"},{"label":"Google Scholar","url":"https://scholar.google.com/citations?user=ZB07UFEAAAAJ&hl=en"}],"papers":[{"title":"Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer","journal":"European Journal of Nuclear Medicine and Molecular Imaging","year":2021,"doi":"10.1007/s00259-020-04934-4"},{"title":"Proposal for systemic-therapy response-assessment criteria at the time of PSMA PET/CT imaging: the PSMA PET progression criteria","journal":"Journal of Nuclear Medicine","year":2020,"doi":"10.2967/jnumed.119.233817"},{"title":"PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0","journal":"European Journal of Nuclear Medicine and Molecular Imaging","year":2023,"doi":"10.1007/s00259-022-06089-w"}]},{"id":"thomas-hope","kind":"person","name":"Thomas A. Hope","aka":[],"tldr":"Nuclear medicine physician who led the trials that got PSMA PET approved in the United States.","summary":"Thomas Hope is Professor of Radiology and Chief of Nuclear Medicine at UCSF, within the UCSF Helen Diller Family Comprehensive Cancer Center. A nuclear medicine physician specialising in PSMA PET and theranostics, his prospective studies of 68Ga-PSMA-11 PET at UCSF and UCLA supported the first FDA approval of PSMA PET in the United States in 2020. His papers include a JAMA Oncology multicentre prospective phase 3 imaging trial of the diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis before radical prostatectomy and a JAMA Oncology prospective single-arm trial assessing its accuracy in localising recurrent prostate cancer. He leads theranostics research and PSMA radioligand dosimetry work in prostate cancer.","asOf":"2026-09-08","links":[{"label":"UCSF profile","url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Thomas%20A.%20Hope"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hope%20TA%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Thomas%20A.%20Hope"}],"tags":[],"related":["ga-68"],"indications":["prostate"],"sections":[],"technologies":["psma-pet","radioligand-therapy","pet"],"targets":["psma"],"drugs":[],"companies":[],"institutions":["ucsf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Radiology; Chief of Nuclear Medicine, UCSF","institutionId":"ucsf","specialisms":["Nuclear medicine","PSMA PET","Theranostics"],"profiles":[{"label":"UCSF profile","url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Thomas%20A.%20Hope"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hope%20TA%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Thomas%20A.%20Hope"}],"papers":[{"title":"Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial","journal":"JAMA Oncology","year":2021,"url":"https://doi.org/10.1001/jamaoncol.2021.3771","doi":"10.1001/jamaoncol.2021.3771"},{"title":"Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial","journal":"JAMA Oncology","year":2019,"url":"https://doi.org/10.1001/jamaoncol.2019.0096","doi":"10.1001/jamaoncol.2019.0096"}]},{"id":"uwe-haberkorn","kind":"person","name":"Uwe Haberkorn","aka":[],"tldr":"Nuclear medicine physician whose group invented FAPI PET tracers and pioneered PSMA and FAP radioligand therapy.","summary":"Uwe Haberkorn is Head of Nuclear Medicine at Heidelberg University Hospital and the German Cancer Research Center (DKFZ). His specialisms are nuclear medicine, FAP-targeted radiopharmaceuticals and theranostics, with a focus on the FAP and PSMA targets. His Heidelberg group invented the quinoline-based FAP inhibitor (FAPI) tracers, and his Journal of Nuclear Medicine paper reported 68Ga-FAPI PET/CT tracer uptake across 28 different kinds of cancer. The group also led early PSMA-617 and FAP-targeted radioligand therapy in humans, and his record links him to FAP-2286 and lutetium-177 vipivotide tetraxetan. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Haberkorn%20U%5BAuthor%5D%20FAPI"}],"tags":[],"related":["ga-68","lu-177"],"indications":[],"sections":[],"technologies":["fapi-pet","radioligand-therapy","psma-pet"],"targets":["fap","psma"],"drugs":["fap-2286","pluvicto"],"companies":[],"institutions":["heidelberg-nct"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["journal-of-nuclear-medicine"],"dependsOn":[],"notes":[],"role":"Head of Nuclear Medicine, Heidelberg University Hospital and DKFZ","institutionId":"heidelberg-nct","specialisms":["Nuclear medicine","FAP-targeted radiopharmaceuticals","Theranostics"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Haberkorn%20U%5BAuthor%5D%20FAPI"}],"papers":[{"title":"68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer","journal":"Journal of Nuclear Medicine","year":2019,"doi":"10.2967/jnumed.119.227967"}]},{"id":"virginia-pappas","kind":"person","name":"Virginia Pappas","aka":[],"tldr":"Long-serving CEO of the Society of Nuclear Medicine and Molecular Imaging.","summary":"Virginia Pappas is Chief Executive Officer of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the principal US professional society for nuclear medicine physicians, scientists and technologists. She leads the society's staff and operations, supporting its scientific meetings, journals and advocacy for molecular imaging and radiopharmaceutical therapy in oncology.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://www.snmmi.org/"}],"tags":["leadership","nuclear medicine"],"related":[],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["snmmi"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer","institutionId":"snmmi","specialisms":["Association management","Nuclear medicine advocacy"],"profiles":[{"label":"Society page","url":"https://www.snmmi.org/"}],"papers":[]},{"id":"wolfgang-weber","kind":"person","name":"Wolfgang A. Weber","aka":[],"tldr":"Nuclear medicine physician who established PET response criteria and leads Munich's radiopharmaceutical development pipeline.","summary":"Wolfgang Weber led the early studies showing FDG-PET response after one cycle of chemotherapy predicts outcome in lung and gastro-oesophageal cancer and helped define PERCIST response criteria. He directs nuclear medicine at TUM, where PSMA ligands and FAP inhibitors were developed, and has been president of the Society of Nuclear Medicine and Molecular Imaging. His current focus is trial design for theranostics.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Weber%20WA%5BAuthor%5D%20PET"}],"tags":["nuclear-medicine","imaging","theranostics"],"related":[],"indications":[],"sections":[],"technologies":["pet","fdg-pet","radioligand-therapy","fapi-pet"],"targets":[],"drugs":[],"companies":[],"institutions":["tum-munich","snmmi"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich","institutionId":"tum-munich","specialisms":["Molecular imaging","PET response assessment","Theranostics","Radiopharmaceutical development"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Weber%20WA%5BAuthor%5D%20PET"}],"papers":[{"title":"Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use","journal":"JCO","year":2003,"doi":"10.1200/JCO.2003.06.120"},{"title":"Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging","journal":"JCO","year":2001,"doi":"10.1200/JCO.2001.19.12.3058"}],"orcid":"0000-0002-7854-4345"},{"id":"wolfgang-fendler","kind":"person","name":"Wolfgang P. Fendler","aka":[],"tldr":"A German nuclear medicine doctor at Essen who helped design a scoring system, RECIP, for reading follow-up PSMA scans in prostate cancer patients on lutetium therapy, and who co-writes the field's international imaging guidelines.","summary":"Wolfgang Fendler is vice chair (deputy director, under Ken Herrmann) and head of translational oncology at the University Hospital Essen's Department of Nuclear Medicine, and a member of the German Cancer Consortium (DKTK). He is first or senior author on a series of studies validating Response Evaluation Criteria in PSMA-PET/CT (RECIP 1.0), a framework for reading follow-up PSMA PET scans in men on 177Lu-PSMA radioligand therapy, and co-authored the EANM/SNMMI joint procedure guidelines for both PSMA PET/CT and 177Lu-PSMA radioligand therapy.\n\nHis research also covers real-world outcomes of extended and rechallenge 177Lu-PSMA-617 therapy in metastatic castration-resistant prostate cancer, and he received the EAU Prostate Cancer Research Award in 2021 for his work relating PSMA-ligand PET findings to clinical outcomes in non-metastatic castration-resistant prostate cancer.","asOf":"2026-09-22","links":[{"label":"Essen Klinik für Nuklearmedizin, oncology team page","url":"https://nuklearmedizin.uk-essen.de/onkologie/"},{"label":"RECIP 1.0, Radiology / RECIP criteria collaboration site","url":"https://recip-criteria.com/"}],"tags":["PSMA","response criteria","clinician"],"related":["essen-wtz","psma-pet","lu177-radioligand-therapy","ken-herrmann","matthias-eiber","lu-177"],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor and Vice Chair (deputy director), Department of Nuclear Medicine, University Hospital Essen / University of Duisburg-Essen","institutionId":"essen-wtz","specialisms":["PSMA PET response assessment","radioligand therapy trials","German Cancer Consortium (DKTK) translational research"],"profiles":[{"label":"Essen nuclear medicine department page","url":"https://nuklearmedizin.uk-essen.de/onkologie/"}],"papers":[{"title":"Novel framework for treatment response evaluation using PSMA PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study","journal":"Journal of Nuclear Medicine","year":2022,"url":"https://recip-criteria.com/"},{"title":"Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)","journal":"European Journal of Nuclear Medicine and Molecular Imaging","year":2023,"doi":"10.1007/s00259-023-06255-8"},{"title":"PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0","journal":"European Journal of Nuclear Medicine and Molecular Imaging","year":2023,"doi":"10.1007/s00259-022-06089-w"}]}]